Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV.

Kendall EA, Durovni B, Martinson NA, Cavalacante S, Masonoke K, Saraceni V, Lebina L, Efron A, Cohn S, Chon S, Chaisson RE, Dowdy DW, Golub JE; THRio and TEKO teams.

AIDS. 2019 Sep 26. doi: 10.1097/QAD.0000000000002380. [Epub ahead of print]

PMID:
31567163
2.

Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.

Kendall EA, Malhotra S, Cook-Scalise S, Denkinger CM, Dowdy DW.

BMC Infect Dis. 2019 Sep 9;19(1):794. doi: 10.1186/s12879-019-4429-x.

3.

Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses.

Kendall EA, Kamoga C, Kitonsa PJ, Nalutaaya A, Salvatore PP, Robsky K, Nakasolya O, Mukiibi J, Isooba D, Cattamanchi A, Kato-Maeda M, Katamba A, Dowdy DW.

PLoS One. 2019 Jul 24;14(7):e0220251. doi: 10.1371/journal.pone.0220251. eCollection 2019.

4.

What will it take to eliminate drug-resistant tuberculosis?

Kendall EA, Sahu S, Pai M, Fox GJ, Varaine F, Cox H, Cegielski JP, Mabote L, Vassall A, Dowdy DW.

Int J Tuberc Lung Dis. 2019 May 1;23(5):535-546. doi: 10.5588/ijtld.18.0217.

PMID:
31097060
5.

Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.

Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX.

AIDS. 2019 Mar 1;33(3):525-536. doi: 10.1097/QAD.0000000000002053.

PMID:
30325773
6.

Would pan-tuberculosis treatment regimens be cost-effective?

Kendall EA, Brigden G, Lienhardt C, Dowdy DW.

Lancet Respir Med. 2018 Jul;6(7):486-488. doi: 10.1016/S2213-2600(18)30197-8. Epub 2018 May 31. Review. No abstract available.

7.

Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis.

Dowdy DW, Theron G, Tornheim JA, Warren R, Kendall EA.

Clin Infect Dis. 2017 Oct 1;65(7):1206-1211. doi: 10.1093/cid/cix486.

8.

Impact of nonintrusive clinical decision support systems on laboratory test utilization in a large academic centre.

Eaton KP, Chida N, Apfel A, Feldman L, Greenbaum A, Tuddenham S, Kendall EA, Pahwa A.

J Eval Clin Pract. 2018 Jun;24(3):474-479. doi: 10.1111/jep.12890. Epub 2018 Feb 15.

9.

Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study.

Kendall EA, Schumacher SG, Denkinger CM, Dowdy DW.

PLoS Med. 2017 Dec 14;14(12):e1002472. doi: 10.1371/journal.pmed.1002472. eCollection 2017 Dec.

10.

Mathematical Modeling of "Chronic" Infectious Diseases: Unpacking the Black Box.

Fojo AT, Kendall EA, Kasaie P, Shrestha S, Louis TA, Dowdy DW.

Open Forum Infect Dis. 2017 Aug 14;4(4):ofx172. doi: 10.1093/ofid/ofx172. eCollection 2017 Fall. Erratum in: Open Forum Infect Dis. 2018 Jan 25;5(1):ofx206.

11.

Linking Individual Natural History to Population Outcomes in Tuberculosis.

Salvatore PP, Proaño A, Kendall EA, Gilman RH, Dowdy DW.

J Infect Dis. 2017 Dec 27;217(1):112-121. doi: 10.1093/infdis/jix555. Erratum in: J Infect Dis. 2018 Apr 20;:.

12.

Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis.

Fojo AT, Stennis NL, Azman AS, Kendall EA, Shrestha S, Ahuja SD, Dowdy DW.

Lancet Public Health. 2017 Jul;2(7):e323-e330. doi: 10.1016/S2468-2667(17)30119-6.

13.

Tuberculosis in children: under-counted and under-treated.

Kendall EA.

Lancet Glob Health. 2017 Sep;5(9):e845-e846. doi: 10.1016/S2214-109X(17)30305-4. No abstract available.

14.

Drug-resistant tuberculosis in 2017: at a crossroads.

Dowdy DW, Theron G, Tornheim JA, Kendall EA.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30081-4. doi: 10.1016/S2213-2600(17)30081-4. [Epub ahead of print] No abstract available.

15.

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.

Kendall EA, Azman AS, Cobelens FG, Dowdy DW.

PLoS One. 2017 Mar 8;12(3):e0172748. doi: 10.1371/journal.pone.0172748. eCollection 2017.

16.

Target regimen profiles for treatment of tuberculosis: a WHO document.

Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M.

Eur Respir J. 2017 Jan 25;49(1). pii: 1602352. doi: 10.1183/13993003.02352-2016. Print 2017 Jan. No abstract available.

17.

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW.

PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan.

18.

Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.

Kendall EA, Cohen T, Mitnick CD, Dowdy DW.

Int J Infect Dis. 2017 Mar;56:185-189. doi: 10.1016/j.ijid.2016.12.010. Epub 2016 Dec 19. Review.

19.

Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.

Kendall EA, Fojo AT, Dowdy DW.

Lancet Respir Med. 2017 Mar;5(3):191-199. doi: 10.1016/S2213-2600(16)30423-4. Epub 2016 Dec 16. Erratum in: Lancet Respir Med. 2017 Feb;5(2):e13.

20.

Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.

Kendall EA, Fofana MO, Dowdy DW.

Lancet Respir Med. 2015 Dec;3(12):963-72. doi: 10.1016/S2213-2600(15)00458-0. Epub 2015 Nov 18.

21.

Transforming the fight against tuberculosis: targeting catalysts of transmission.

Dowdy DW, Azman AS, Kendall EA, Mathema B.

Clin Infect Dis. 2014 Oct 15;59(8):1123-9. doi: 10.1093/cid/ciu506. Epub 2014 Jun 30. Review.

22.

Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study.

Kendall EA, Theron D, Franke MF, van Helden P, Victor TC, Murray MB, Warren RM, Jacobson KR.

PLoS One. 2013 Dec 13;8(12):e83480. doi: 10.1371/journal.pone.0083480. eCollection 2013.

23.

Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa.

Jacobson KR, Theron D, Kendall EA, Franke MF, Barnard M, van Helden PD, Victor TC, Streicher EM, Murray MB, Warren RM.

Clin Infect Dis. 2013 Feb;56(4):503-8. doi: 10.1093/cid/cis920. Epub 2012 Oct 22.

24.

Medically unexplained illness and the diagnosis of hysterical conversion reaction (HCR) in women's medicine wards of Bangladeshi hospitals: a record review and qualitative study.

Kendall EA, Zaman RU, Naved RT, Rahman MW, Kadir MA, Arman S, Azziz-Baumgartner E, Gurley ES.

BMC Womens Health. 2012 Oct 22;12:38. doi: 10.1186/1472-6874-12-38.

25.

Molecular determinants of proteolytic disassembly of the reovirus outer capsid.

Doyle JD, Danthi P, Kendall EA, Ooms LS, Wetzel JD, Dermody TS.

J Biol Chem. 2012 Mar 9;287(11):8029-38. doi: 10.1074/jbc.M111.334854. Epub 2012 Jan 17.

26.

Relatedness of Vibrio cholerae O1/O139 isolates from patients and their household contacts, determined by multilocus variable-number tandem-repeat analysis.

Kendall EA, Chowdhury F, Begum Y, Khan AI, Li S, Thierer JH, Bailey J, Kreisel K, Tacket CO, LaRocque RC, Harris JB, Ryan ET, Qadri F, Calderwood SB, Stine OC.

J Bacteriol. 2010 Sep;192(17):4367-76. doi: 10.1128/JB.00698-10. Epub 2010 Jun 28.

27.

Leptospirosis as a cause of fever in urban Bangladesh.

Kendall EA, LaRocque RC, Bui DM, Galloway R, Ari MD, Goswami D, Breiman RF, Luby S, Brooks WA.

Am J Trop Med Hyg. 2010 Jun;82(6):1127-30. doi: 10.4269/ajtmh.2010.09-0574.

28.

Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh.

Kendall EA, Tarique AA, Hossain A, Alam MM, Arifuzzaman M, Akhtar N, Chowdhury F, Khan AI, Larocque RC, Harris JB, Ryan ET, Qadri F, Calderwood SB.

Infect Immun. 2010 Jan;78(1):253-9. doi: 10.1128/IAI.00868-09. Epub 2009 Oct 26.

29.

Memory T-cell responses to Vibrio cholerae O1 infection.

Weil AA, Arifuzzaman M, Bhuiyan TR, LaRocque RC, Harris AM, Kendall EA, Hossain A, Tarique AA, Sheikh A, Chowdhury F, Khan AI, Murshed F, Parker KC, Banerjee KK, Ryan ET, Harris JB, Qadri F, Calderwood SB.

Infect Immun. 2009 Nov;77(11):5090-6. doi: 10.1128/IAI.00793-09. Epub 2009 Aug 24.

30.

Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Kendall EA, González E, Espinoza I, Tipismana M, Verdonck K, Clark D, Vermund SH, Gotuzzo E.

J Pediatr. 2009 Nov;155(5):700-6. doi: 10.1016/j.jpeds.2009.05.027. Epub 2009 Jul 22.

31.

Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh.

Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, Kendall EA, Rahman A, LaRocque RC, Wrammert J, Ryan ET, Qadri F, Calderwood SB, Harris JB.

Infect Immun. 2009 Sep;77(9):3850-6. doi: 10.1128/IAI.00369-09. Epub 2009 Jun 15.

32.

Probing the mechanism of FET3 repression by Izh2p overexpression.

Kupchak BR, Garitaonandia I, Villa NY, Mullen MB, Weaver MG, Regalla LM, Kendall EA, Lyons TJ.

Biochim Biophys Acta. 2007 Jul;1773(7):1124-32. Epub 2007 Apr 13.

33.

Using composite health status measures to assess the nation's health.

Erickson P, Kendall EA, Anderson JP, Kaplan RM.

Med Care. 1989 Mar;27(3 Suppl):S66-76.

PMID:
2921888
34.

The role of the veterinarian in the future.

Kendall EA.

Aust Vet J. 1988 Feb;65(2):54-60. No abstract available.

PMID:
3281644

Supplemental Content

Loading ...
Support Center